A Novel Staphylococcus aureus Vaccine: Iron Surface Determinant B Induces Rapid Antibody Responses in Rhesus Macaques and Specific Increased Survival in a Murine S. aureus Sepsis Model
- 1 April 2006
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (4) , 2215-2223
- https://doi.org/10.1128/iai.74.4.2215-2223.2006
Abstract
Staphylococcus aureus is a major cause of nosocomial infections worldwide, and the rate of resistance to clinically relevant antibiotics, such as methicillin, is increasing; furthermore, there has been an increase in the number of methicillin-resistant S. aureus community-acquired infections. Effective treatment and prevention strategies are urgently needed. We investigated the potential of the S. aureus surface protein iron surface determinant B (IsdB) as a prophylactic vaccine against S. aureus infection. IsdB is an iron-sequestering protein that is conserved in diverse S. aureus clinical isolates, both methicillin resistant and methicillin sensitive, and it is expressed on the surface of all isolates tested. The vaccine was highly immunogenic in mice when it was formulated with amorphous aluminum hydroxyphosphate sulfate adjuvant, and the resulting antibody responses were associated with reproducible and significant protection in animal models of infection. The specificity of the protective immune responses in mice was demonstrated by using an S. aureus strain deficient for IsdB and HarA, a protein with a high level of identity to IsdB. We also demonstrated that IsdB is highly immunogenic in rhesus macaques, inducing a more-than-fivefold increase in antibody titers after a single immunization. Based on the data presented here, IsdB has excellent prospects for use as a vaccine against S. aureus disease in humans.Keywords
This publication has 44 references indexed in Scilit:
- Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX®) in hemodialysis patientsVaccine, 2004
- Staphylococcus aureusCapsular PolysaccharidesClinical Microbiology Reviews, 2004
- Real-Time Monitoring of Bacterial Infection In Vivo: Development of Bioluminescent Staphylococcal Foreign-Body and Deep-Thigh-Wound Mouse Infection ModelsAntimicrobial Agents and Chemotherapy, 2003
- Passage of Heme-Iron Across the Envelope of Staphylococcus aureusScience, 2003
- Protective Immunity of Pneumococcal GlycoconjugatesCritical Reviews in Microbiology, 2003
- Overproduction of Type 8 Capsular Polysaccharide AugmentsStaphylococcus aureusVirulenceInfection and Immunity, 2002
- Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureusProceedings of the National Academy of Sciences, 2002
- Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving HemodialysisNew England Journal of Medicine, 2002
- Population‐Based Incidence and Characteristics of Community‐OnsetStaphylococcus aureusInfections with Bacteremia in 4 Metropolitan Connecticut Areas, 1998The Journal of Infectious Diseases, 2001
- Vaccination with Staphylococcus aureus fibrinogen binding proteins (FgBPs) reduces colonisation of S. aureus in a mouse mastitis modelFEMS Immunology & Medical Microbiology, 1994